India, Nov. 15 -- Johnson & Johnson (JNJ) is close to acquiring eye disease drug developer Ollin Biosciences in a deal valued at up to $3.4 billion, according to a Financial Times report citing people familiar with the matter.
The proposed transaction could include an upfront cash payment of about $2.2 billion, with an additional $1.2 billion tied to future milestone achievements. The deal could be announced as early as Monday, although discussions are ongoing and may still fall through.
Ollin Biosciences, a privately held company backed by Arch Venture Partners and Mubadala Capital, is developing a treatment aimed at two major causes of severe vision loss in older adults.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-156...